ADIM
ALNY icon

Alpha DNA Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Alpha DNA Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,019
Closed -$710K – 17
2024
Q4 		$710K Buy
+3,019
New +$794K 0.27% 84
2024
Q2 		– Sell
-5,129
Closed -$767K – 203
2024
Q1 		$767K Buy
5,129
+409
+9% +$68.2K 0.28% 80
2023
Q4 		$903K Buy
+4,720
New +$804K 0.35% 53

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpha DNA Investment Management's ALNY Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 3,019 shares — an estimated $710K sold.

Alpha DNA Investment Management first reported a position in ALNY in Q4 2023 and held it in 3 quarters. The position peaked at $903K in Q4 2023. 626 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 3,019 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $710K.
  • Alpha DNA Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Alpha DNA Investment Management's Alnylam Pharmaceuticals position peaked at $903K in Q4 2023.
  • 626 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.